Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QWINT-3: LY3209590 vs insulin degludec in type 2 diabetes on basal insulin
jRCT2031220018Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in HbA1c at Week 26. Started Apr 2022; status: active, not recruiting.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031220018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220018.